NCT00680225

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: New England Retina Associates · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Accepted

Summary

To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.

Conditions

• Choroidal Melanoma

Interventions

Type	Name	Description
DRUG	Ranibizumab injection and TTT - ICG based	Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.

Timeline

• Start date: 2007-09-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2008-05-20
• Last updated: 2017-04-12
• Results posted: 2017-04-12

Locations

1 site across 1 country: United States